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cured without valve surgery; it was cured with a 30-month 
antimicrobial drug regimen (10). 
The role for serial serologic testing in assessing cure 
of Bartonella endocarditis is unknown. In our cases, as in 
a previous report (10), a drop in Bartonella titers occurred 
over a 3-year period in those who were cured, suggesting 
follow-up serologic testing might be useful to assess Bar-
tonella endocarditis clinical cure.
Our findings suggest that a simple, inexpensive drug 
regimen is optimal therapy for Bartonella endocarditis and 
that serial serologic testing can confirm adequate treatment 
and cure. Further research is needed to validate this ap-
proach to managing Bartonella endocarditis.
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We tested whole-blood and plasma samples from immuno-
competent patients who had had benign Zika virus infec-
tions and found that Zika virus RNA persisted in whole blood 
substantially longer than in plasma. This finding may have 
implications for diagnosis of acute symptomatic and asymp-
tomatic infections and for testing of blood donations.
Since cases of severe neurologic disorders among adults (1) and fetal abnormalities (2) linked to Zika virus 
infections were initially reported, the World Health Or-
ganization has deemed the Zika virus outbreak a “public 
health emergency of international concern” and has raised 
Zika virus to the same level of concern as Ebola virus. In 
response, medical authorities from many countries have 
released advice and guidelines regarding prevention and 
diagnosis to contain the spread of this virus and guidelines 
regarding safety of whole blood and blood components. 
In August 2016, the Food and Drug Administration an-
nounced universal testing for Zika virus RNA in donated 
whole blood and blood components taken in the United 
States and its territories using a qualitative molecular assay 
on plasma specimens (3).
In Europe, advice on Zika virus regarding the safety of 
substances of human origin (4) has been applied in France 
since February 15, 2016. A qualitative individual molecu-
lar test for Zika virus RNA in plasma specimens is being 
used on whole-blood specimens from blood donors living 
in Guadeloupe and Martinique, 2 overseas administrative 
areas where Zika virus is autochthonous. Furthermore, in 
mainland France and in French overseas areas where no 
active Zika virus transmission exists, and since the begin-
ning of the Zika virus outbreak in 2015, blood donors who 
have recently visited areas or countries with ongoing Zika 
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virus transmission are subject to a 28-day temporary defer-
ral after their departure from these areas, a period twice the 
assumed maximum incubation period for Zika virus. Simi-
larly, temporary deferral applies to blood donors who have 
a sex partner who has been recently infected or potentially 
exposed to a confirmed or suspected Zika virus infection 
within the previous 3 months.
We report results from a 2016 longitudinal follow-up 
of Zika virus RNA quantification in EDTA whole-blood and 
plasma samples taken from 5 immunocompetent patients (2 
men, 33 and 70 years of age, and 3 women, 55, 58, and 67 
years of age) and results from a point-to-point comparison 
of Zika viral loads on both EDTA whole-blood and cor-
responding plasma samples (27 pairs). We extracted RNA 
by using the MagNA Pure 96 instrument with the DNA and 
Viral NA Small Volume Kit (Roche Diagnostics, Meylan, 
France) (input and output volumes 200 and 100 µL). We 
quantified RNA by using the RealStar Zika RNA RT-PCR 
kit 1.0 (Altona Diagnostics GmbH, Hamburg, Germany) 
(limit of selection 2.48 log copies/mL). We always suc-
cessfully detected the manufacturer’s internal control. All 
samples were collected from patients who had returned 
from the Caribbean or South and Central America and had 
had a benign form of Zika virus infection.
Results from the follow-up (18 whole-blood and 
21 plasma samples) showed that the median duration of 
Zika virus was 22 (range 14–100) days in whole blood 
and 10 (range 7–37) days in plasma (p = 0.058). Mean 
viral loads of positive samples were 3.39 log copies/mL 
in whole blood (n = 13) and 2.52 log copies/mL in plasma 
(n = 6; p = 0.001). Viral loads in the last positive samples 
varied from 2.7 to 3.9 log copies/mL in whole blood and 
2.2  to 2.8 log copies/mL in plasma (p = 0.06). Whole-
blood samples from 2 patients remained positive at 14 and 
63 days after their plasma samples had become negative 
(Figure, panel A).
The point-to-point comparison (18 pairs from the 
follow-up and 9 additional pairs) showed that Zika virus 
RNA was quantifiable in 23 whole-blood specimens but in 
only 10 plasma samples. Mean viral load was 3.50 (range 
2.75–4.17) log copies/mL in whole blood and 3.01 (range 
2.21–4.10) log copies/mL in plasma (p< = 0.018) (Figure, 
panel B).
These data show that Zika virus RNA persisted in 
whole blood after it disappeared in plasma. Similar results 
have been reported previously for West Nile virus, also a 
member of the Flaviviridae family (5,6), and for Zika virus 
with a qualitative in-house PCR (7).
Our data have 3 main consequences. First, for acute 
symptomatic infection, the use of whole blood extends the 
period of diagnosis. Second, for asymptomatic infections 
with a high likelihood of low viral load, virus detection 
in plasma might be less sensitive than detection in whole-
blood specimens. Third, according to our data that show 
that viremia can persist for >28 days after symptom on-
set, recommendations used to reduce the risk for Zika virus 
transmission through blood or blood components should be 
modified. Potential options such as extending the deferral 
period or testing blood donations for Zika virus RNA in 
whole blood should be considered.
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Figure. A) Zika virus viremia in whole blood and plasma from 5 immunocompetent patients in France (identified by sex and age, y) who 
had traveled to Central or South America or the Caribbean. B) Zika viral load in whole-blood (n = 23) and plasma (n = 10) samples from a 
point-to-point comparison of positive samples. Horizontal lines indicate mean ± SE. LOD, limit of detection; PL, plasma; WB, whole blood.
Overall, our data show that use of whole-blood speci-
mens is much more sensitive than use of plasma samples to 
detect Zika virus RNA. These data could be useful in rec-
ommending the use of whole blood instead of plasma for 
the molecular diagnosis of acute symptomatic and asymp-
tomatic Zika virus infections and for the safety of whole 
blood and blood components from donors, as well as for 
the safety of organs, tissues, and cells from deceased and 
living donors.
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We describe a case of methicillin-resistant Staphylococcus 
aureus (MRSA) enterocolitis in a healthy adult with previous 
antibiotic exposure. Colonoscopy revealed diffuse colitis 
and mild ileitis without ulceration. Stool cultures demon-
strated abundant growth of MRSA and absent normal flora. 
Oral vancomycin treatment was effective and seems to be 
the consensus choice for therapy.
Staphylococcus aureus was recognized as a cause of an-tibiotic-associated colitis (AAC) in the mid-20th cen-
tury (1,2). Clostridium difficile was later identified as the 
primary cause of AAC, and appreciation of S. aureus as a 
potential etiology declined (2). Methicillin-resistant S. au-
reus (MRSA) has also been implicated as a cause of AAC, 
with most reports coming from Japan. We report a case of 
MRSA enterocolitis in Canada caused by a strain harboring 
multiple enterotoxins.
In 2014, a 22-year-old woman sought care after 10 
days of acute and profuse diarrhea, abdominal cramping, 
nausea, and weight loss of 5 lbs. She had 10–30 bowel 
movements a day and had observed blood-tainted stool. 
The patient reported a history of migraine and depression 
but was otherwise healthy. She worked in a pet store and 
had not been hospitalized. In the previous 2 months, she 
had been treated for chlamydia with a single course of 
azithromycin and cefixime. Subsequently, she received 
a 10-day course of azithromycin followed by 10 days of 
moxifloxacin for bronchopneumonia. Her family history 
revealed Crohn’s colitis in her father.
The patient was afebrile; blood pressure was 104/58 
mm Hg and pulse 91 bpm. Her abdomen was soft with-
out rebound tenderness. Laboratory test results revealed a 
normal leukocyte count but a C-reactive protein level of 
76 mg/L. Her initial diagnosis was with bacterial enteritis, 
and she was sent home with an order for stool cultures and 
oral ciprofloxacin to be started after stool collection. On 
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